Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Omega-3 wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Mixed evidence
1 of 3 studies with measurable effects showed benefit.
Top outcomes
Verdict
Probably helps
18 of 27 studies with measurable effects showed benefit.
Top outcomes
Shared outcomes (1)
Outcomes where both DHM and Omega-3 have evidence — compare verdict strength side-by-side.
300-600mg before or after drinking; 300mg daily for liver support
Before drinking alcohol, Before bed after drinking, Daily for liver support
Dihydromyricetin capsules or tablets
2-3g combined EPA+DHA daily
With meals containing fat
Triglyceride form fish oil
Weeks (ongoing)
Acute
Next day
4-8 weeks
2-4 weeks
Immediate
4-12 weeks
Polyphenols as potential metabolism mechanisms regulators in liver protection and liver cancer prevention
Cell proliferation (2023) · Systematic review
This review systematically illustrates that various polyphenols, including resveratrol, chlorogenic acid, caffeic acid, dihydromyricetin, quercetin, catechins, curcumin, etc., improve metabolic disorders through direct or indirect pathways to protect the liver and fight liver cancer.
Flavonoids-mediated SIRT1 signaling activation in hepatic disorders
Life sciences (2020) · Systematic review
Additionally, molecular modeling simulations were applied to explore the potential binding mode of these flavonoids to SIRT1.
Metabolic mechanisms of Dihydromyricetin and strategies for enhancing its bioavailability: A recent review
Food chemistry (2025) · Systematic review
It examines the key factors influencing its bioavailability and highlights the design and construction of various bio-based delivery systems aimed at improving its bioavailability.
Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer
The New England journal of medicine (2019) · Rct · n=25871
During a median follow-up of 5.3 years, a major cardiovascular event occurred in 386 participants in the n-3 group and in 419 in the placebo group (hazard ratio, 0.92; 95% confidence interval [CI], 0.80 to 1.06; P=0.24).
Omega-3 fatty acids for intermittent claudication
The Cochrane database of systematic reviews (2024) · Meta analysis · n=1830
Omega-3 compared with a control may have little to no effect on ankle-brachial index (MD -0.02, 95% CI -0.08 to 0.04; 3 studies, 168 participants; very low-certainty evidence).
A systematic review and meta-analysis of the omega-3 fatty acids effects on brain-derived neurotrophic factor (BDNF)
Nutritional neuroscience (2024) · Meta analysis · n=587
The present systematic review and meta-analysis indicate the efficacy of omega-3 FAs in increasing the serum concentration of BDNF.
Evidence primarily from systematic reviews examining polyphenol hepatoprotective mechanisms rather than direct DHM clinical trials. Bioavailability limitations may reduce actual effectiveness. Conservative estimates given lack of specific dose-response studies.
Based on multiple meta-analyses showing EPA-dominant formulas >1g/day most effective. Effects plateau around 2-2.5g. Adjunctive use with antidepressants shows better outcomes than monotherapy.
AI-estimated from published studies. Interpret as directional guidance.
Omega-3 has a higher evidence score (9/10 vs 4/10) and wins in 2 of 3 categories.
For reduce inflammation, Omega-3 has a higher relevance score (90 vs 75).
No known interactions between DHM and Omega-3 have been documented in our database. However, always consult a healthcare provider before combining supplements.